Contralateral prophylactic mastectomy - Predictors of significant histologic findings

被引:89
作者
Goldflam, K
Hunt, KK
Gershenwald, JE
Singletary, SE
Mirza, N
Kuerer, HM
Babiera, GV
Ames, FC
Ross, MI
Feig, BW
Sahin, AA
Arun, B
Meric-Bernstam, F
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
关键词
breast carcinoma; risk-reducing mastectomy; prophylactic mastectomy; Gail model; lobular carcinoma;
D O I
10.1002/cncr.20617
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Women with unilateral breast carcinoma are at increased risk for developing contralateral breast carcinoma (CBC). The authors sought to identify predictors of malignant or moderate to high-risk histologic findings in contralateral prophylactic mastectomy (CPM) specimens, and to determine the efficacy of CPM. METHODS. The authors performed a retrospective review of 239 patients with unilateral early-stage breast carcinoma who underwent CPM. The number of CBCs expected if the contralateral breast had been left intact was calculated based on CBC rates observed in the Surveillance, Epidemiology, and End Results (SEER) database and on life-table analysis by family history. RESULTS. In the current study, 11 patients (4.6%) had occult contralateral malignancies (4 invasive carcinomas and 7 ductal carcinomas in situ) and 44 (18.4%) patients had moderate to high-risk pathology (8 lobular carcinoma in situ, 11 atypical lobular hyperplasia, 25 atypical ductal hyperplasia). At 1846 patient-years of follow-up, only 1 patient (0.4%) developed a new CBC compared with 11 expected cancers based on SEER data. One CBC was observed among 140 patients with a family history of breast carcinoma, compared with 16 expected cancers based on life-table analysis adjusted for adjuvant therapy. The determinants of significant findings at CPM were invasive lobular histology, estrogen and progesterone receptor positivity, additional ipsilateral moderate to high-risk pathology, and age > 40 years at cancer diagnosis. CONCLUSIONS. CPM was associated with a low risk of subsequent development of breast carcinoma. Evaluation of histologic findings in the ipsilateral breast may help to predict the likelihood of significant disease in the contralateral breast and assist in risk stratification. (C) 2004 American Cancer Society.
引用
收藏
页码:1977 / 1986
页数:10
相关论文
共 36 条
  • [21] Prophylactic mastectomy
    Newman, LA
    Kuerer, HM
    Hunt, KK
    Vlastos, G
    Ames, FC
    Ross, MI
    Singletary, SE
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2000, 191 (03) : 322 - 330
  • [22] The long and short of chromosome 11 in breast cancer
    Newsham, IF
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (01) : 5 - 9
  • [23] Page DL, 1996, CANCER, V78, P258, DOI 10.1002/(SICI)1097-0142(19960715)78:2<258::AID-CNCR11>3.0.CO
  • [24] 2-V
  • [25] Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study
    Page, DL
    Schuyler, PA
    Dupont, WD
    Jensen, RA
    Plummer, WD
    Simpson, JF
    [J]. LANCET, 2003, 361 (9352) : 125 - 129
  • [26] ANATOMIC INDICATORS (HISTOLOGIC AND CYTOLOGIC) OF INCREASED BREAST-CANCER RISK
    PAGE, DL
    DUPONT, WD
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1993, 28 (02) : 157 - 166
  • [27] Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer
    Peralta, EA
    Ellenhorn, JDI
    Wagman, LD
    Dagis, A
    Andersen, JS
    Chu, DZJ
    [J]. AMERICAN JOURNAL OF SURGERY, 2000, 180 (06) : 439 - 445
  • [28] Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers:: The PROSE study group
    Rebbeck, TR
    Friebel, T
    Lynch, HT
    Neuhausen, SL
    van't Veer, L
    Garber, JE
    Evans, GR
    Narod, SA
    Isaacs, C
    Matloff, E
    Daly, MB
    Olopade, OI
    Weber, BL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1055 - 1062
  • [29] Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations
    Schrag, D
    Kuntz, KM
    Garber, JE
    Weeks, JC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (05): : 617 - 624
  • [30] Seynaeve C, 2003, BREAST CANCER RES TR, V82, pS179